Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Partner Bristol Myers Squibb Announces Confirmatory Trial For KRAZATI Meets Primary Endpoint

April 1 (Reuters) - Zai Lab Ltd  9688.HK :
    * ZAI LAB PARTNER BRISTOL MYERS SQUIBB ANNOUNCES PIVOTAL
KRYSTAL-12 CONFIRMATORY TRIAL EVALUATING KRAZATI (ADAGRASIB)
MEETS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL FOR PATIENTS
WITH PRETREATED KRASG12C-MUTATED LOCALLY ADVANCED OR
METASTATIC...
    * ZAI LAB LTD:  EXPECTS TO SUBMIT NDA FOR ADAGRASIB TO NMPA
FOR
KRAS(G12C) MUTATED NSCLC IN SECOND OR LATER LINE TREATMENT IN
CHINA THIS YEAR.
    * ZAI LAB LTD: FDA ASSIGNED A PRESCRIPTION DRUG USER FEE ACT
(PDUFA) GOAL DATE OF JUNE 21, 2024

Source text for Eikon:  ID:nBw2vql7Ha 
Further company coverage:  9688.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news